Quantcast
Home > Quotes > XBIT

XBiotech Inc. Common Stock (XBIT) Quote & Summary Data

XBIT 
$8.22
*  
0.38
4.42%
Get XBIT Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading XBIT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
13
Today's High / Low
$ 8.71 / $ 8.07
Share Volume
142,623
50 Day Avg. Daily Volume
178,016
Previous Close
$ 8.60
52 Week High / Low
$ 11.74 / $ 2.13
Market Cap
337,114,407
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.63
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.71

Intraday Chart

Shares Traded

Share Volume:
142,623
50 Day Avg. Daily Volume:
178,016

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.63

Trading Range

The current last sale of $8.22 is 285.92% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.71 $ 11.74
 Low: $ 8.07 $ 2.13

Company Description (as filed with the SEC)

XBiotech Inc. ("XBiotech" or the "Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human(TM) monoclonal antibodies for treating a variety of diseases. True Human(TM) monoclonal antibodies are those which occur naturally in human beings--as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human(TM) pipeline and manufacturing system. The majority of our efforts to date have been concentrated on developing our lead product candidate, bermekimab (also known as MABp1, Xilonix(TM), CA-18C3, CV-18C3, RA-18C3, and T2-18C3), a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1a).  ... More ...  



Risk Grade

Where does XBIT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8.65
Open Date:
Aug. 23, 2019
Close Price:
$ 8.22
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info